United States set
language
Menu Shopping cart $0 Search
Manufactured by BioVendor

fastGEN BCR::ABL1 Cancer Kit

  • Regulatory status:RUO
  • Type:NGS - Next generation sequencing
  • Species:Human
Cat. No. Size Price


New RDNGS0011 16 samples (1 kit)
PubMed Product Details
Technical Data

Bioinformatic analysis software: GENOVESA

The GENOVESA fastGEN software module, available online, can to be used to analyse sequencing data. It is a cloud all-in-one solution for the analysis of raw data (FASTQ format files) with technical and application support.

Visit GENOVESA

Type

NGS - Next generation sequencing

Description

Compatible with all Illumina platforms, for other platforms use conversion kit.

Reconstitution

No

Applications

Isolated DNA

Note


BioVendor Group fastGEN: A breakthrough system for one-step NGS library

Summary

Research topic

Oncology

Summary

The BCR::ABL1 fusion gene is the most important genetic marker for chronic myeloid leukemia. Patients with Philadelphia chromosome-positive leukemia patients may benefit from three generations of tyrosine kinase inhibitors.

Hyperactivation of the oncogenic tyrosine kinase ABL1 leads to cell cycle aberrations. Increased genomic instability coupled with reduced repair capacity leads to accumulation of secondary mutations, conformational changes, ineffectiveness of some tyrosine kinase inhibitors and treatment failure.

There is a need to diagnose the mutational status of these variants and their response to current treatment options and possibly develop new targeted molecular therapies. The fastGEN BCR::ABL1 Cancer kit from BioVendor Group is the first commercial NGS-based solution capable of covering the three most common breakpoint cluster regions, major, minor and micro.

Together with our fastGEN Cancer kits for TP53 and isocitrate dehydrogenase; BCR::ABL1 Cancer kit will be a useful tool to improve treatment options for hemato-oncology patients worldwide.

Related Products Docs